Positive multi-center COPD trial with inhaled Bimosiamose
Revotar Biopharmaceuticals AG announced that it successfully completed a multi-center Phase II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD). Data have been accepted for the annual congress of the European Respiratory Society (ERS) in Amsterdam.
Inhalation of Bimosiamose for 28 days on top of standard bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD (GOLD II-III). It led to a broad and significant attenuation of airway inflammation and trend towards lung function improvements.
"Our data with Bimosiamose demonstrate a significant step forward in the anti-inflammatory treatment of COPD", said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar. "We will discuss future clinical development of our first in class inhaled drug with international key opinion leaders in Amsterdam at one of the biggest and renowned respiratory conferences worldwide."
Other news from the department research and development
